Department of Health and Human Services, through National Institutes of Health, awarded Mapp Biopharmaceutical, Inc. of San Diego, CA $1,986,788 under the SBIR program (Phase III), with work starting 2025-09-24 and running to 2028-08-31. It is one of 2 SBIR and STTR awards Mapp Biopharmaceutical, Inc. received in the last two years, $2,281,371 in all. Each figure links to the federal record.
The award
| Recipient | Mapp Biopharmaceutical, Inc. (San Diego, CA) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase III |
| Amount obligated | $1,986,788 |
| Period of performance starts | 2025-09-24 |
| Period of performance ends | 2028-08-31 |
| Award number | SB1AI191871 (grant, CFDA 93.855) |
| Assistance listing | 93.855, Allergy and Infectious Diseases Research |
| Place of performance | San Diego, San Diego County, CA |
| Recipient registry id (UEI) | M9V9QTHR1H28 |
Want the whole picture on Mapp Biopharmaceutical, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Mapp Biopharmaceutical, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Mapp Biopharmaceutical, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
Development of highly potent human monoclonal for rsv immunoprophylaxis - project summary globally, respiratory syncytial virus (rsv) causes over 3 million hospitalizations of neonates/infants. While there are licensed v
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-08-25 | Continuation | 000 | $993,435 |
| 2025-09-24 | New | 000 | $993,353 |
Development of highly potent human monoclonal for rsv immunoprophylaxis - project summary globally, respiratory syncytial virus (rsv) causes over 3 million hospitalizations of neonates/infants. While there are licensed vaccines in the u.s. For use in elderly populations, they are neither approved nor appropriate for use in neonates/infants who have immature immune systems. Palivizumab, a prophylactic monoclonal antibody (mab) marketed by astrazeneca and sobi as synagis™, has been available since 1998, but due to high cost and modest efficacy, its use has been restricted to high-risk infants. The recently approved single dose, long-acting mab, nirsevimab (previously known as MEDI8897 and marketed as beyfortus™ by sanofi), has improved efficacy compared to palivizumab and was approved for use in all children up to 24 months of age. However, severe shortages and cost barriers have limited its availability in countries where IT is currently approved (EU, US, japan, australia, canada and china). In october 2023 the CDC issued health alert network CDCHAN-00499 that recommended limiting the use of nirsevimab to higher risk children in the 2023- 2024 season due to the shortages, resulting in many eligible infants not receiving prophylaxis. In addition, nirsevimab is not currently available in any low- or middle-income countries (lmics) and is unavailable in 8/10 of the most populous co ...
From the federal award record.
Other SBIR and STTR awards to Mapp Biopharmaceutical, Inc.
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2025-06-09 | Department of Health and Human Services | SBIR Phase I | $294,583 | A novel cost-effective multispecific therapeutic for dengue - project summary dengue remai (record) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Mapp Biopharmaceutical, Inc.Look up Mapp Biopharmaceutical, Inc. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.